Home > PJ (current issue) > Letters | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 269 No 7221 p605-608
26 October 2002

This page
Reprint
Photocopy

   

PDF 68K

Letters

  Supervision
  Sociology
  Advertising
  Media
  CPD
  Materia Medica
  The profession
  Herbal medicines
  Patient packs


Letters to the Editor

  * PDF files on PJ Online require Acrobat Reader 4 or later.

Herbal medicines

Directive is impossible in practice

From Dr R. J. Woodward, MRPharmS

It is nonsense for the Medicines Control Agency to claim that the effect on industry of the proposed herbal directive will be minimal (PJ, 19 October, p560).


The excellent reports of the International Pharmaceutical Federation meetings on 4 September (PJ, 21 September, p403) put the herbal medicines problems and difficulties into practical perspective. Linda Anderson’s reference to harmonisation of requirements for safety, quality and efficacy resulting from adoption of the directive is something of a pipe dream when we learn of the complexity of herbal ingredients and products. Dr Lang (p405) tells us that of the six best documented products one is kava. Then there are the 2,000 component herbal product mixtures. The substantial differences in release patterns of ingredients from hard and soft gelatin capsules are unbelievable. Few comprehensive monographs and consistent specifications are available.

Surely this is enough for the regulators to realise that although a directive may be desirable to satisfy their yearn for control, what is currently on offer is impossible in practice. The industry does not have either the financial resources or skills to meet the technical demands envisaged in the directive. Indeed, many would argue that the inherent variability of herbs make such demands unachievable. Equally, regulatory resources, even if the manpower and skills were available, to police such a directive properly would be vast and poor value for the consumer.

In the present state of knowledge, the only practical way forward is to introduce a registration system including a negative list, good manufacturing practice and realistic purity standards to detect adulteration and known trace toxic contaminants. Claims should be based on traditional use backed with labelling and promotional caveats.

Such a system would establish a level playing field for
marketers and manufacturers whereas what is currently proposed is potentially a charter for the less scrupulous elements on both sides.

Robert Woodward
Liss, Hampshire

 

Send your letter to The Editor

Previous Topic (The profession)
Next Topic (Patient packs)

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal